Novamind Inc.

Novamind Inc.

Novamind Unveils Stealth Mode Investment in Alto Neuroscience

TORONTO, ON / ACCESSWIRE / October 22, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind"), a leading mental health company specialized in psychedelic medicine, is pleased to unveil Alto Neuroscience ("Alto"), a clinical-stage biopharmaceutical company, as its previously announced stealth mode investment. In June 2021, Novami... Read More...

Novamind Launches New Psychedelic Palliative Care Program

Specialized program to research and scale access to psychedelic medicine opens new doors for patients with chronic and serious illnessTORONTO, ON / ACCESSWIRE / October 7, 2021 /Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind"), a leading mental health company specialized in psychedelic medicine, is pleased to launch Psychedelic P... Read More...

Novamind Announces DTC Eligibility for its Common Shares

TORONTO, ON / ACCESSWIRE / September 24, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC") in the U.S.The DT... Read More...

Novamind Opens 5th Clinic Location Specialized in Integrative Psychiatry for Patients with Treatment-Resistant Conditions

Company executes organic growth mandate, on track to open four new clinics by Q3 2021TORONTO, ON / ACCESSWIRE / July 29, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has completed the construction of a new clinic foc... Read More...

Novamind Has Applied to Have its Common Shares Posted for Trading on the OTCQB in the United States

Aims to increase visibility and facilitate investment for United States investorsTORONTO, ON / ACCESSWIRE / July 21, 2021 /Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has submitted its application to have its common shares... Read More...